A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients (original) (raw)
Current dilemmas in antimicrobial therapy in cystic fibrosis
kamini Jain
Expert Review of Respiratory Medicine, 2012
View PDFchevron_right
Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis
Meenu Singh
The Scientific World Journal, 2013
View PDFchevron_right
Infection in patients with cystic fibrosis
Thomas Rubio
The American Journal of Medicine, 1986
View PDFchevron_right
Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis
Ismail Khan
Journal of Antimicrobial Chemotherapy, 1982
View PDFchevron_right
Antibiotic therapy of pulmonary infections in cystic fibrosis. Dosage schedules and duration of treatment
Birgitta Strandvik
Chest, 1988
View PDFchevron_right
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Harry Heijerman
European Respiratory Journal, 2000
View PDFchevron_right
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
Catherine M T Sherwin
Pediatric Pulmonology, 2013
View PDFchevron_right
Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?
Raphael Rangel
The Journal of Pediatrics, 1980
View PDFchevron_right
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials
Luis Máiz
Expert Opinion on Pharmacotherapy, 2013
View PDFchevron_right
Microbiology of airway disease in a cohort of patients with cystic fibrosis
Fabio Rossano
BMC infectious diseases, 2006
View PDFchevron_right
Inhalation of antibiotics in cystic fibrosis
Daan Touw
European Respiratory Journal
View PDFchevron_right
State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary
David Young
Pediatric Pulmonology, 2021
View PDFchevron_right
Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa
Kenneth Rand
Journal of Microbiology and Infectious Diseases, 2017
View PDFchevron_right
Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
Murray Barclay
Journal of Antimicrobial Chemotherapy, 1996
View PDFchevron_right
Recent Approach in Microbial Pathogen Complications in Patients with Cystic Fibrosis
Salah Abdelbary
Clarivate, 2020
View PDFchevron_right
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections
Catherine Byrnes
Clinical Infectious Diseases, 2019
View PDFchevron_right
Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre
M. Cruciani
View PDFchevron_right
Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
James Slaven
SAGE open medicine, 2017
View PDFchevron_right
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients
Javier Gracia
Clinical Microbiology and Infection, 2005
View PDFchevron_right
Inhaled antibiotics in cystic fibrosis: what's new?
Simon Langton-Hewer
JRSM, 2012
View PDFchevron_right
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Jay Hilliard
American Journal of Respiratory and Critical Care Medicine, 2003
View PDFchevron_right
Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis
Ribhi Shawar
The Journal of Infectious Diseases, 1999
View PDFchevron_right
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005
Donald R VanDevanter
Journal of Cystic Fibrosis, 2013
View PDFchevron_right
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis; Do the Benefits Outweigh the Harms?
Ada Kong
American journal of respiratory and critical care medicine, 2018
View PDFchevron_right
Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients
G. Loeuille, Dominique Turck, P. Vic
European Journal of Pediatrics, 1996
View PDFchevron_right
Treatment of Lower Respiratory Tract Infections Due to Pseudomonas aeruginosa in Patients with Cystic Fibrosis
Daniel Caplan
Clinical Infectious Diseases, 1984
View PDFchevron_right
Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience
Kelvin D MacDonald
The clinical respiratory journal, 2012
View PDFchevron_right
Pseudomonas aeruginosa among Cystic Fibrosis patients: epidemiology, risk factors and infection control
Can AKIN
2020
View PDFchevron_right
Advanced cystic fibrosis lung disease in children
Marlyn Woo
Current Opinion in Pulmonary Medicine, 2001
View PDFchevron_right
Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Joseph McCormack
Australian and New Zealand journal of medicine, 1999
View PDFchevron_right